Articles
27. 10. 2015 Cancer in the older population of the Czech Republic
Population ageing has become a challenge to cancer care in developed countries. Particularities of the older population must be taken into account when considering cancer treatment. However, there is a lack of consensus on guidelines for this population due to the underrepresentation of older patients in clinical trials.
15. 1. 2014 Personalised invitations of Czech citizens to cancer screening programmes
In January 2014, a project of personalised invitations for cancer screening programmes was launched in the Czech Republic. In particular, citizens are invited to participate in colorectal cancer screening (men and women), as well as breast cancer screening and cervical cancer screening (women). Personalised invitations are aimed at citizens who have not participated in cancer screening programmes in the long term, and therefore are at a higher risk of developing cancer. The project is expected to increase participation rates in Czech cancer screening programmes.
» Archive
CAR-TOOL
The aim of the project is to collect and evaluate data from real clinical practice, which are related to the administration of CAR-T cell therapy in patients with certain hematological malignancies who face poor prognosis. CAR-T cell therapy is currently indicated in adult patients with certain types of non-Hodgkin's lymphoma, incl. aggressive, relapsing or refractory diffuse large B-cell lymphoma, primary mediastinal B-lymphoma, high-grade B-lymphoma, transformed follicular lymphoma and mantle cell lymphoma; and in pediatric patients and patients under 25 years of age with acute lymphoblastic leukemia (B-ALL) who do not respond to a defined number of standard therapy lines.
start projektu: January 2021
Primary objectives
- Evaluation of the effectiveness of CAR-T cell therapy based on treatment response (ORR, CR) and patient survival (OS, PFS).
- Evaluation of the incidence and severity of side effects of CAR-T cell therapy.
- Assessment of the effect of previous treatment, comorbidities and disease status on the parameters evaluated in objectives 1 and 2.
- Monitoring CAR-T expansion and persistence in the patient's peripheral blood and evaluating the association with response and toxicity.
- Monitoring of selected cytokines after CAR-T administration and evaluation of the association with toxicity.
Secondary objectives
Monitoring the number of treated patients for an overview of the current situation and discussion with health care payers. Evaluation of the risk-benefit balance in assessing the indication and for optimizing the process of selecting patients for treatment with CAR-T cell therapy.
Expert guarantors
The guarantor of the register is MUDr. Frantisek Folber, Ph.D. (University Hospital Brno Department of Internal Hematology and Oncology).
Project management is provided by the Institute of Biostatistics and Analyzes, s.r.o., a spin-off company of Masaryk University.
Michal jetelina, Project Manager
Petr Brabec, Executive Officer
